Remove tag standard-care
article thumbnail

Haemophilia drug costing $3.5m per dose has been approved

Pharmafile

CSL Behring’s haemophilia B gene therapy has recently been approved by US regulators, however the treatment has an enormous price tag. The treatment also seemed to free 94% of patients from expensive and time-consuming infusions of Factor IX, which is the current standard of care for the often fatal condition. Costing $3.5m

72
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag

pharmaphorum

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. The post FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag appeared first on. Preliminary results from that study showed a 53.8%

FDA 111
article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. The standard of care for the condition includes blood transfusions, hydroxyurea and iron chelation. Topic sponsors are not involved in the creation of editorial content.

FDA 59
article thumbnail

2021 Highlights of Chronic Care Medicine

PharmD Live

Virtual care a boon for underserved chronic care populations. Virtual care, normalized by the pandemic, is now common practice for providers and patients, especially at the primary care level–a boon in 2021 for underserved chronic care populations. New Standard for Blood Pressure in Chronic Kidney Disease.

FDA 52
article thumbnail

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

pharmaphorum

The designation – which is awarded to therapies that could represent a significant improvement over standard of care in either efficacy, safety, or both – has been awarded on the strength of phase 1 results in patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC).

FDA 72
article thumbnail

Versanis’ bimagrumab, first-in-class obesity therapy, enters Phase IIb of development

Pharmaceutical Technology

Nonetheless, patients receiving the current standard of care, Novo Nordisk’s Wegovy (injectable semaglutide), are expected to self-administer treatment on a weekly basis. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies.